[Recommendations of antifungal treatment in patients with low grade immunosuppression].
Because of the relevance that the systemic mycoses has acquired in non-highly immunocompromised patients, the treatment difficulties they have due to the increase of the non-albicans Candida species and the need to have a better and more rational use of the new antifungal agents (voriconazole, posaconazole, caspofungin, anidulafungin and micafungin), an experts' panel on infectious diseases in representation of the Spanish Society of Chemotherapy, Spanish Society of Internal Medicine, and Spanish Society of Pneumology and Thoracic Surgery has met in order to make a few recommendations based on the scientific evidence in an effort to improve their efficiency.
Sociedad Española de Medicina Interna (SEMI), Madrid. josebarberan@telefonica.net
J
J
Barberán
J
J
Mensa
C
C
Fariñas
P
P
Llinares
R
R
Serrano
R
R
Menéndez
C
C
Agustí
M
M
Gobernado
J R
JR
Azanza
J A
JA
García Rodríguez
D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000382:microbiology; D016469:Fungemia / Q000188:drug therapy; D006801:Humans; D016867:Immunocompromised Host; D008172:Lung Diseases, Fungal / Q000188:drug therapy; D016921:Meningitis, Fungal / Q000188:drug therapy; D009181:Mycoses / Q000188:drug therapy*
D000935:Antifungal Agents